Rigotti 2006.

Methods	BUPROPION Randomized controlled trial Setting: hospitals, USA Recruitment: volunteers
Participants	248 smokers hospitalised with cardiovascular disease (excludes 3/3 dropped prior to treatment & 2 placebo deaths during follow up) 31% F, av age 56, av CPD 23/21. 30%/20% had prior use of bupropion, 54%/56% prior use of NRT
Interventions	1. Bupropion 300 mg for 12w 2. Placebo Both arms: Multicomponent CBT cessation & relapse prevention programme, motivational interviewing approach, Begun in hospital, 30‐45 mins, 5 X10 min post‐discharge contacts (2 days,1,3,8, 12w), S‐H, chart prompt for physician. Total time 80‐95 mins
Outcomes	Abstinence at 12m (sustained at multiple follow ups) Validation: saliva cotinine at 12 & 52w, CO at 2 & 4w
Notes	Funding: National Heart, Lung and Blood Institute, National Institutes of Health General Clinical Research Centers Program, GlaxoSmithKline
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Using a computer program, the study statistician generated a sequence of randomly‐permuted blocks of 4 within strata formed by study site and daily cigarette consumption (10 vs 10)."
Allocation concealment (selection bias)	Low risk	"The study pharmacist used this sequence, concealed from enrolment staff, to assign participants to study arm. Subjects and study personnel, except the statistician and pharmacist, were blind to treatment assignment."
Blinding (performance bias and detection bias) All outcomes	Low risk	"Subjects and study personnel, except the statistician and pharmacist, were blind to treatment assignment."
Incomplete outcome data (attrition bias) All outcomes	Low risk	"Subjects were considered smokers if they were lost to follow‐up..."; 23% lost to follow up in the bupropion group and 23% in the placebo group.